Goodwin represented PAREXEL International Corporation (NASDAQ: PRXL) in the completion of its agreement to be acquired by Pamplona Capital Management, LLP for $88.10 per share in cash in a transaction valued at approximately $5.0 billion. The transaction was approved by stockholders, with more than 98% of votes cast in favor. PAREXEL stock will stop trading at the close of business on September 29. Josef von Rickenbach will continue to serve as CEO. Dr. Jeremy Gelber, Partner of Pamplona Capital Management, will serve on the board of directors.
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and has approximately 19,600 employees.
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. Pamplona manages over $10 billion in assets across a number of funds for a variety of clients including public pension funds, international wealth managers, multinational corporations, family offices, and funds of hedge funds.